TEVA
Teva Pharmaceutical Industries Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$41.31
−0.46%Oct 12, 2026, 21:45 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD announced that it will host an R&D Day in New York City on November 11, 2026.
Oct 12, 2026, 17:10 UTC
Teva expects to launch Weltruza in the United States soon.
Source:Oct 10, 2026, 19:00 UTC
Teva shares closed 2% higher in Tel Aviv and MedinCell SA shares rose 16.9% in Paris.
Source:Oct 9, 2026, 11:00 UTC
The U.S. Food and Drug Administration approved Teva’s WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia.
Oct 9, 2026, 05:45 UTC
The Royal College of Pharmacy ended TEVA PHARMACEUTICAL INDUSTRIES LTD’s sponsorship and exhibition arrangement for its forthcoming annual conference, part of a £15,000 deal covering four events.
Source:Oct 3, 2026, 14:45 UTC
A Russian air strike on Friday, Oct. 2 set fire to a pharmaceutical storage warehouse belonging to Ukrainian drug distributor Venta near Kyiv, destroying inventories of medicines made by Bayer, Sanofi, Pfizer, Teva, Darnytsia and Farmak.
Source:Oct 2, 2026, 12:00 UTC
Teva Pharmaceuticals presented new efficacy and safety data for ecopipam, an investigational treatment for pediatric Tourette syndrome, at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, South Korea.
Oct 2, 2026, 06:30 UTC
The Royal College of Nursing ended its commercial partnership with Teva UK and dropped the firm as sponsor of its 30 October 2026 migraine and headache services event in London.
Oct 1, 2026, 08:30 UTC
Samsung Biologics and Teva Pharmaceutical expanded their strategic partnership to advance the development of up to six biosimilar candidates.
Sep 28, 2026, 20:00 UTC
The U.S. FDA approved Teva Pharmaceutical Industries' DEGEVMA (denosumab-adet), a biosimilar to Xgeva, for preventing bone complications in advanced cancer, treating giant cell tumor of bone, and treating hypercalcemia of malignancy.
Source:Sep 23, 2026, 20:45 UTC
Teva Pharmaceutical Industries announced it will release its third quarter 2026 financial results and host a conference call on November 3, 2026.
Source:Sep 19, 2026, 11:00 UTC
The Delhi High Court ruled that a ₹1,851 crore payment made by Ranbaxy Laboratories to Teva Israel under a settlement agreement is not taxable in India, allowing Teva Israel's refund subject to guarantees.
Source:Sep 18, 2026, 20:32 UTC
Teva Pharmaceuticals announced new data from a discrete choice experiment on healthcare provider treatment preferences for VMAT2 inhibitors in tardive dyskinesia in older patients, presented at Psych Congress in New Orleans.
Source:Sep 18, 2026, 20:31 UTC
Teva Pharmaceuticals announced new real-world data showing UZEDY (risperidone) extended-release injectable suspension helps schizophrenia patients remain on treatment longer while reducing emergency care and healthcare costs compared with other long-acting injectables, presented at Psych Congress in New Orleans.
Source:Sep 18, 2026, 20:30 UTC
Teva Pharmaceuticals presented new post hoc data from the pivotal SOLARIS Phase 3 trial for olanzapine LAI (TEV-'749), a once-monthly subcutaneous long-acting injectable for treating schizophrenia in adults, at Psych Congress in New Orleans.
Source:Sep 15, 2026, 12:49 UTC
Teva Pharmaceutical Industries Ltd. completed a major debt refinancing.
Source:Sep 14, 2026, 21:52 UTC
Teva Pharmaceuticals moved its shares from American Depositary Receipts to direct trading on the New York Stock Exchange.
Source:Sep 14, 2026, 12:03 UTC
Teva Pharmaceutical Industries began trading its ordinary shares directly on the New York Stock Exchange, marking a milestone in its pivot to growth strategy.
Sep 10, 2026, 10:04 UTC
Teva Pharmaceutical Industries priced an offering of approximately $4.9 billion (equivalent) of senior notes, with net proceeds to fund redemptions of certain existing notes and for general corporate purposes.
Source:Sep 8, 2026, 23:59 UTC
The Jacksonville Palestine Solidarity Network announced a campaign urging the Jacksonville Police and Fire Pension Fund to divest from Teva Pharmaceuticals, citing the company's Israeli ties and opioid litigation history.
Source:Sep 7, 2026, 08:00 UTC
Teva Pharmaceutical Industries announced its intention to issue EUR- and USD-denominated senior notes through its special purpose finance subsidiaries Teva Finance II, III, and IV, with proceeds to fund redemptions of certain existing notes and pay related fees.
Sep 2, 2026, 11:03 UTC
Teva announced positive topline results from its Phase 2a study of TEV '408, an anti-IL-15 antibody for celiac disease, showing significant prevention of gluten-induced intestinal damage.
Sep 1, 2026, 01:55 UTC
CSL signed agreements with the Trump administration to lower medicine prices in the US, including discounts for Medicaid and price-matching for new therapies, to avoid 100% tariffs.
Source:Aug 31, 2026, 20:07 UTC
Teva Pharmaceuticals and the Trump Administration announced a shared commitment to reach an agreement to lower Medicaid drug prices and enhance supply chain security for U.S. patients.
Source:Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Jul 30, 2026, 17:26 UTC
Teva Pharmaceutical Industries reported Q2 2026 earnings that missed estimates due to Emalex acquisition costs, but revenue beat expectations driven by innovative drugs.
Source:
Page 1Next →